Serum Vitamin D Levels Affect Pathologic Complete Response in Patients Undergoing Neoadjuvant Systemic Therapy for Operable Breast Cancer

Akiko Chiba(Wake Forest University), William Jacot(Inserm), Sarah L. Mott(University of Iowa), Stéphane Pouderoux(Institut de Recherche en Cancérologie de Montpellier), Marie Viala(Institut de Recherche en Cancérologie de Montpellier), Mary C. Schroeder(University of Iowa), R. Ganapathi Raman(University of Iowa), Pierre‐Jean Lamy(Montpellier GenomiX), Simon Thézenas(Institut de Recherche en Cancérologie de Montpellier), Alexandra Thomas(Cliniques Universitaires Saint-Luc)
Clinical Breast Cancer
December 11, 2017
10.1016/j.clbc.2017.12.001
Cited by 23

Related Papers

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
|The Lancet|2022|664
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial
|Cancer Cell|2021|330
ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer
|Annals of Oncology|2023|298